Loading
IH
Integer Holdings Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Nov 2025.
Integer Holdings Corp: what insiders have been doing
Integer Holdings Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 35 filings signed by 18 insiders.
Purchases and sales both appear in the filings: 4 purchases (4 insiders, €432k) and 4 sales (2 insiders, €3.6M). On balance, insiders were net sellers of €3.1M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 3 senior executives and 1 chief executive. At €2.2M, the sale published on 16 September 2026 by Thor Kirk K is the largest of the period (0.057% of market cap).
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 13 November 2025, 339 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 35 filings, this issuer sits above that mark. Our records for Integer Holdings Corp go back to 2016, with 5 purchases and 19 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.85 bn USD and net income of 102.8 m USD.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
225
Thresholds
n/a
Buy Volume
€665,295
5 ops. · all time
Sell Volume
€8M
19 ops. · all time
Who traded when
BuySaleKirk K. Thor2 sales
Tommy P. Thomas2 sales
Cheryl C. Capps1 buy
Diron Smith1 buy
John A. Harris1 buy
Payman Khales1 buy
Since the insiders bought
- +22.8%Entry US$69.49 · Close at T+90 US$85.36
- +22.4%Entry US$69.82 · Close at T+90 US$85.46
- +22.4%Entry US$69.82 · Close at T+90 US$85.46
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,774 of 24,148 companies
41.7
score / 100
Value41
Quality42
FCF yld2.4%
Earn yld2.4%
EV/EBITDA19.2x
ROE7.5%
Gross mgn27%
Net mgn5.5%
Debt/EBITDA4.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$126.61
Analyst consensus
5 analysts3.00/5
US$101.00Target US$121.80(-4%)US$127.00
Income statement
RevenueUS$1.9B
Gross profitUS$500.4M27% margin
EBITDAUS$292.4M16% margin
Net incomeUS$102.8M7.0% margin
Valuation
PER (trailing)34.6x
PER (forward)18.4x
P/Book2.5x
Beta0.58
Balance sheet & cash
Market capUS$4.3B
Total debtUS$1.3B
Free Cash FlowUS$105.1M
Debt / Equity79%
Profitability & ownership
ROE7.5%
ROA3.9%
% insiders0.9%
% institutions137.5%
Last declaration on 16 September 2026
Declarations225 total
19,773 shares@ US$126.25450.057% mcap29.2% of flowCommon StockSEC:0001726955-26-000010:0
11,767 shares@ US$126.22550.034% mcap17.4% of flowCommon StockSEC:0001726955-26-000010:1
4,700 shares@ US$126.300.014% mcap7.0% of flowCommonSEC144:0001959173-26-006988
31,540 shares@ US$126.200.091% mcap46.4% of flowCommonSEC144:0001949846-26-000581
9,408 shares@ US$126.300.027% mcap67.4% of flowCommonSEC144:0001959173-26-006773
1,967 shares0Common StockSEC:0001843602-26-000002:0
1,967 shares0Common StockSEC:0001233311-26-000002:0
1,967 shares0Common StockSEC:0001843623-26-000002:0
1,842 shares@ US$88.0016.9% of flowCommon StockSEC:0001689261-26-000004:1
3,837 sharesCommon StockSEC:0001689261-26-000004:0
410 shares0Common StockSEC:0002122528-26-000006:0
410 shares0Common StockSEC:0002055648-26-000008:0
1,350 sharesCommon StockSEC:0002068698-26-000005:0
1,777 sharesCommon StockSEC:0001894063-26-000005:0
825 shares@ US$85.0022.1% of flowCommon StockSEC:0001730071-26-000007:0
798 shares0Common StockSEC:0001977225-26-000005:0
7,389 shares0Common StockSEC:0001731729-26-000006:0
4,475 shares0Common StockSEC:0001726955-26-000005:0
2,691 shares0Common StockSEC:0001978852-26-000004:0
2,340 shares0Common StockSEC:0001916725-26-000003:0
923 shares0Common StockSEC:0001730071-26-000005:0
218 sharesCommon StockSEC:0001730071-26-000003:0
551 sharesCommon StockSEC:0001726955-26-000002:0
758 sharesCommon StockSEC:0001978852-26-000002:0
1,359 sharesCommon StockSEC:0001977225-26-000003:0
25 of 225 declarations
About Integer Holdings Corp
Integer Holdings Corp. (NYSE: ITGR) is a U.S.-listed healthcare manufacturing company focused on medical device contract development and manufacturing. Based on the company’s investor materials, Integer is one of the largest medical device CDMOs in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. Its commercial brands include Greatbatch Medical® and Lake Region Medical®, reflecting a portfolio built around engineering-intensive, high-reliability medical technology solutions. ([investor.integer.net](https://investor.integer.net/overview/?utm_source=openai))
The company’s roots trace back to Greatbatch, Inc., which was renamed Integer Holdings Corporation in 2016. That change marked a broader repositioning around a more integrated identity and an emphasis on advanced engineering and manufacturing for medical device customers. Integer’s headquarters are in Plano, Texas, United States, and the company serves customers across a global footprint, while remaining firmly anchored in the U.S. capital markets through its listing on the NYSE. ([investor.integer.net](https://investor.integer.net/news-events/press-releases/news-details/2016/Greatbatch-Inc-Renamed-Integer-Holdings-Corporation/default.aspx?utm_source=openai))
Read moreShow less
Operationally, Integer’s value proposition is end-to-end: design support, development, manufacturing, quality systems, and scale production. The company’s core strength lies in helping original equipment manufacturers move complex medical technologies from concept to commercialization faster and with lower development risk. Its capabilities span implantable and precision components, device subassemblies, and products used in cardiac rhythm management and neuromodulation therapies. In a sector where regulatory compliance, precision, and supply reliability matter enormously, that integrated model is a key competitive advantage. ([investor.integer.net](https://investor.integer.net/overview/?utm_source=openai))
From a competitive standpoint, Integer is positioned as a scaled specialist rather than a broad diversified healthcare conglomerate. Its differentiation comes from deep technical know-how, long-term customer relationships, a broad and diversified product pipeline, and exposure to attractive end markets with structural growth drivers. Those factors can support recurring program wins and make the company strategically important to major medtech OEMs. ([investor.integer.net](https://investor.integer.net/news-events/press-releases/news-details/2026/Integer-Announces-Strategic-Review-to-Maximize-Stockholder-Value/default.aspx?utm_source=openai))
Recent developments are especially relevant for investors. On April 30, 2026, Integer announced a strategic review aimed at maximizing shareholder value, including the possibility of a sale, merger, or strategic business combination. The company also reported first-quarter 2026 results showing sales of $440 million and a cautious update to its outlook, while reiterating its longer-term target of returning to 200 basis points above-market organic sales growth in 2027. For investors tracking SEC Form 4 insider transactions, this combination of strategic review, operational execution, and capital structure evolution makes ITGR a closely watched name. ([investor.integer.net](https://investor.integer.net/news-events/press-releases/news-details/2026/Integer-Announces-Strategic-Review-to-Maximize-Stockholder-Value/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
